Q-omics provides the consensus-scored RNASEH2CP1 profile across patient tissues and cancer cell-line models. RNASEH2CP1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNASEH2CP1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RNASEH2CP1 RNA expression shows 4,439 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight HNSC, KIRC, and PRAD as cancer lineages where RNASEH2CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASEH2CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASEH2CP1 survival associations across molecular data types. RNASEH2CP1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASEH2CP1 RNA expression–survival associations across cancer types. High RNASEH2CP1 expression shows unfavorable associations in KICH, LGG, DLBC and KIRC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNASEH2CP1 RNA expression.
This table summarizes RNASEH2CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNASEH2CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASEH2CP1 shows lower tumor expression in KIRC, LUAD, KICH, PRAD and STAD and higher tumor expression in LUSC. The KIRC box plot shows higher RNASEH2CP1 RNA expression in normal versus tumor tissue (log2 FC = −0.059, t-test p < 0.001).
This table shows molecular features associated with RNASEH2CP1 in patient tissues and cancer cell lines. In patient samples, RNASEH2CP1 shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set.
